Medium materiality5/10
UBS raises Eli Lilly price target to $1,625
Why it may matterVerify against the original reporting
Bullish analyst update with meaningful implied upside; a single firm's target is not a guarantee.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raised its LLY price target to $1,625, about 18% above the reported $1,373 price. The raised target supports a bullish view, though it remains an analyst opinion.
- UBS price target: $1,625; reported price: $1,373.
Key facts
- 01
Target: $1,625
- 02
Posted price: $1,373
- 03
Analyst firm: UBS
- 04
Analyst: Michael Yee
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.